This site is intended for Healthcare Professionals only.

NPA commissions Professor David Taylor to evaluate impact of inflation on community pharmacies


Share post:

The National Pharmacy Association (NPA) has commissioned Professor David Taylor of University College London to investigate the implications of all-time high inflation rates on community pharmacies in the UK.

Professor Taylor’s will assess rates of inflation affecting community pharmacy across the UK, using public data sources whilst examining inflated costs in the context of the current five year contractual framework in England (2019-2024).

He would review the EY (Ernst & Young) report into pharmacy funding, to identify whether current inflationary pressures could change any of the findings and consider the policy implications and impacts of inflationary pressures, including pharmacy’s ability to prepare for a more clinically focused future and maintain current core services.

NPA chief executive Mark Lyonette said: “Inflationary pressures are eating into the limited funds provided by the NHS for pharmacy services. We believe the real level of inflation for pharmacy businesses could be higher than the CPI inflation rate, which itself is at a 40 year high. Staff and locum costs in the sector as well as medicines costs have risen dramatically.

“Everyone accepts there is a cost of living crisis; it’s time for government and NHS to acknowledge that our members are facing a ‘cost of doing business’ crisis. We believe that is standing in the way of service improvements and our ability to engage with a clinical future.

“By asking a distinguished academic to test our assumptions, we will have credible independent data to present to commissioners and pharmacy negotiators across the UK. Naturally we want this to lead to fair and realistic financial settlements for NPA members right across the UK.”

Professor Taylor said: “With GP practices under increasing pressure and their numbers falling, NHS community pharmacy could do more to enhance clinical outcomes in the English primary care system, as it is in other UK nations such as Scotland. I am committed to contrasting and analysing community pharmacy funding and developing policies as rigorously as possible from a public interest based standpoint.”

The report is due for publication this autumn.


Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

ABPI: Increased pharma exports could boost GDP by £16.3 billion

ABPI urges political leaders to enhance healthcare and economic growth through strategic partnership The Association of the British Pharmaceutical...

The Importance Of Expanding Access To Dental Care For Rural And Undeserved Populations

In many rural areas and underserved neighborhoods, a critical issue is quietly emerging. Although often overlooked, its effects...

BGMA: More than 50% of UK generics face shortages without licensed alternatives

Brexit blamed by BGMA CE, Mark Samuels, as UK faces critical shortages in generic drug supply A recent report...

Paul Burden elected BGMA Vice-Chair, bringing 25 years of industry leadership

Veteran of off-patent sector to drive strategic engagement and patient access initiatives at BGMA The British Generic Manufacturers Association...